Clinical Trial Update: Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months [Phase 3]

View source ↗

Summary

An open-label Phase 3 trial evaluating the safety and efficacy of Sodium Zirconium Cyclosilicate for up to 12 months in patients with hyperkalemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperkalemia

Drugs mentioned

• Sodium Zirconium Cyclosilicate (sodium zirconium cyclosilate)

Snippet

Sponsor: ZS Pharma, Inc. | Conditions: Hyperkalemia | Phase 3 | Status: COMPLETED | Results posted: 2018-06-27